Oncology nurse pride How Have Your Family Experiences With Cancer Impacted Your Decision to Become an Oncology Nurse? June 09, 2017
Genetics & genomics The Story of Henrietta Lacks Sheds Light on Ethical Considerations in Genetic Testing April 28, 2017
Topic Multiple Myeloma Multiple Myeloma Bortezomib May Improve Outcomes in Multiple Myeloma Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet. April 12, 2017 U.S. Food and Drug Administration (FDA) FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma On February 22, 2017, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. February 23, 2017 Multiple Myeloma Statin Use May Improve Overall Survival From Multiple Myeloma A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology. January 10, 2017 Multiple Myeloma New Treatments and Insights in Multiple Myeloma An interview with Beth Faiman, PhD, CNP, and Kimberly Noonan, NP June 03, 2016 Cancer treatments Multiple Myeloma Is Incurable but Treatable This content was developed by ONS, Beth Faiman, PhD, CNP, and Kimberly Noonan, NP, and is sponsored by Amgen. Faiman and Noonan received no payment for their participation. April 05, 2016 Combination therapy FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. July 24, 2015 Clinical Practice The Case of the Mind-Altering Mineral Hal is a 73-year-old patient with refractory multiple myeloma. Florence, his wife, calls the hematologist’s office and asks to speak with the triage nurse. She says she is worried about her husband and that “he’s just not himself.” What would you do? November 19, 2013 Trending Topics Safety Research Standards Treatments ONS Congress Clinical Practice Immunotherapy U.S. Food and Drug Administration (FDA) Cancer research Nursing education View All Topics
Multiple Myeloma Bortezomib May Improve Outcomes in Multiple Myeloma Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet. April 12, 2017
U.S. Food and Drug Administration (FDA) FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma On February 22, 2017, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. February 23, 2017
Multiple Myeloma Statin Use May Improve Overall Survival From Multiple Myeloma A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology. January 10, 2017
Multiple Myeloma New Treatments and Insights in Multiple Myeloma An interview with Beth Faiman, PhD, CNP, and Kimberly Noonan, NP June 03, 2016
Cancer treatments Multiple Myeloma Is Incurable but Treatable This content was developed by ONS, Beth Faiman, PhD, CNP, and Kimberly Noonan, NP, and is sponsored by Amgen. Faiman and Noonan received no payment for their participation. April 05, 2016
Combination therapy FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. July 24, 2015
Clinical Practice The Case of the Mind-Altering Mineral Hal is a 73-year-old patient with refractory multiple myeloma. Florence, his wife, calls the hematologist’s office and asks to speak with the triage nurse. She says she is worried about her husband and that “he’s just not himself.” What would you do? November 19, 2013
